🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Tirzepatide and cholesterol — March 2026 Page 3

Tirzepatide and cholesterol — March 2026

paige_pharma Tue, Dec 16, 2025 at 4:18 AM 37 replies 1,549 viewsPage 3 of 8
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Dec 16, 2025 at 2:29 PM#11
TinaHashiRN said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

Before/after bloodwork compilation for the lipid panel — everything in one place for those who want comprehensive data:

CategoryMarkerBeforeAfter 13moChange
MetabolicA1C7.2%5.5%⬇️ 1.4%
MetabolicFasting Glucose13190⬇️ 26
LipidsLDL14993⬇️ 41
LipidsTriglycerides221121⬇️ 111
InflammationhsCRP6.50.9⬇️ 5.0

Every single metabolic marker improved. This is why I'm a believer in this therapy.

37 12tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 34 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Dec 16, 2025 at 6:38 PM#12
Dr.RaviCardio said:
Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg.

Saving this. It is the first explanation that did not require me to already understand it. Taking it to my next appointment.

36 11ricardo_MIA, BrianDallas92, labquiet_amy and 33 others
Reply Quote Save Share Report
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Dec 16, 2025 at 10:47 PM#13
TinaHashiRN said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

35 10bri_stats, pete_manc_UK, anna.melb_AU and 32 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Dec 17, 2025 at 2:57 AM#14
paige_pharma said:
Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.

Advanced lipoprotein testing on the lipid panel — going beyond standard lipid panel:

MarkerBaselineMonth 8Clinical Meaning
LDL-P17011001Particle count (more precise than LDL-C)
Small dense LDL56%33%Atherogenic pattern
Remnant cholesterol3315Triglyceride-rich lipoproteins
oxLDL6639Oxidative stress marker

The shift from small dense to large buoyant LDL is particularly important — it represents a fundamental change in the atherogenic profile.

Last edited: Dec 17, 2025 at 3:57 AM
34 9DebRD_ATL, KristenIndy, MarkLI_maint and 31 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Dec 17, 2025 at 7:07 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. No action needed from anybody.

Last edited: Dec 17, 2025 at 11:07 AM
33 8PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 30 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register